Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer
- PMID: 36773612
- DOI: 10.1016/S2468-1253(22)00402-2
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer
Conflict of interest statement
We declare no competing interests.
Comment in
-
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer - Authors' reply.Lancet Gastroenterol Hepatol. 2023 Mar;8(3):211-212. doi: 10.1016/S2468-1253(23)00006-7. Lancet Gastroenterol Hepatol. 2023. PMID: 36773613 No abstract available.
Comment on
-
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65. doi: 10.1016/S2468-1253(22)00335-1. Epub 2022 Oct 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36328033 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous